GlucoTrack, Inc. (GCTK)
NASDAQ: GCTK · Real-Time Price · USD
5.68
-0.12 (-2.03%)
Aug 14, 2025, 11:26 AM - Market open
GlucoTrack Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
3.22M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GCTK News
- 8 days ago - Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology - GlobeNewsWire
- 14 days ago - Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting - GlobeNewsWire
- 5 weeks ago - Glucotrack Announces Repurchase of Series A Warrants - GlobeNewsWire
- 7 weeks ago - Why Is This Nano-Cap Glucotrack Stock Trading Higher On Wednesday? - Benzinga
- 7 weeks ago - Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 2 months ago - Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements - GlobeNewsWire
- 2 months ago - Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 2 months ago - Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD - GlobeNewsWire